SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Johansson Peter L.) srt2:(2005-2009)"

Sökning: WFRF:(Johansson Peter L.) > (2005-2009)

  • Resultat 1-10 av 13
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Heard-Costa, Nancy L, et al. (författare)
  • NRXN3 is a novel locus for waist circumference : a genome-wide association study from the CHARGE Consortium
  • 2009
  • Ingår i: PLoS genetics. - : Public Library of Science (PLoS). - 1553-7404. ; 5:6, s. e1000539-
  • Tidskriftsartikel (refereegranskat)abstract
    • Central abdominal fat is a strong risk factor for diabetes and cardiovascular disease. To identify common variants influencing central abdominal fat, we conducted a two-stage genome-wide association analysis for waist circumference (WC). In total, three loci reached genome-wide significance. In stage 1, 31,373 individuals of Caucasian descent from eight cohort studies confirmed the role of FTO and MC4R and identified one novel locus associated with WC in the neurexin 3 gene [NRXN3 (rs10146997, p = 6.4×10−7)]. The association with NRXN3 was confirmed in stage 2 by combining stage 1 results with those from 38,641 participants in the GIANT consortium (p = 0.009 in GIANT only, p = 5.3×10−8 for combined analysis, n = 70,014). Mean WC increase per copy of the G allele was 0.0498 z-score units (0.65 cm). This SNP was also associated with body mass index (BMI) [p = 7.4×10−6, 0.024 z-score units (0.10 kg/m2) per copy of the G allele] and the risk of obesity (odds ratio 1.13, 95% CI 1.07–1.19; p = 3.2×10−5 per copy of the G allele). The NRXN3 gene has been previously implicated in addiction and reward behavior, lending further evidence that common forms of obesity may be a central nervous system-mediated disorder. Our findings establish that common variants in NRXN3 are associated with WC, BMI, and obesity.
  •  
2.
  •  
3.
  • Iversen, Peter, et al. (författare)
  • Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer : updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years
  • 2006
  • Ingår i: Scandinavian Journal of Urology and Nephrology. - London : Taylor & Francis. - 0036-5599 .- 1651-2065. ; 40:6, s. 441-452
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: The Early Prostate Cancer (EPC) programme is evaluating the efficacy and tolerability of bicalutamide following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with localized (T1-2, N0/Nx) or locally advanced (T3-4, any N; or any T, N + ) non-metastatic prostate cancer. Herein we report the latest findings after a median follow-up period of 7.1 years from the Scandinavian Prostate Cancer Group (SPCG)-6 study, one of three trials in the EPC programme. MATERIAL AND METHODS: A total of 1218 patients were randomized on a 1:1 basis to either bicalutamide 150 mg/day (n=607) or placebo (n=611) following standard care; 81.4% were followed conservatively (watchful waiting). The primary endpoints were objective progression-free survival (PFS) and overall survival (OS). RESULTS: In patients with localized disease there was no significant difference in PFS [hazard ratio (HR) 0.85; 95% CI 0.69-1.06; p=0.15] and a trend towards decreased OS with bicalutamide plus standard care compared with standard care alone (HR 1.23; 95% CI 0.96-1.58; p=0.11). In patients with locally advanced disease, bicalutamide significantly improved PFS, reducing the risk of progression by 53% compared with standard care alone (HR 0.47; 95% CI 0.37-0.59; p<0.001). The median time to progression was 8.8 years for bicalutamide plus standard care and 7.1 years for standard care alone. There was a significant improvement in OS with bicalutamide plus standard care, with a reduction in the risk of death of 35% versus standard care alone (HR 0.65; 95% CI 0.50-0.85; p=0.001). CONCLUSION: This analysis of the SPCG-6 study showed that bicalutamide plus standard care offers significant PFS and OS benefits for patients with locally advanced disease, but not for those with localized disease.
  •  
4.
  •  
5.
  • Abramowicz, Marek A, 1945, et al. (författare)
  • No Observational Constraints from Hypothetical Collisions of Hypothetical Dark Halo Primordial Black Holes with Galactic Objects
  • 2009
  • Ingår i: Astrophysical Journal. - 0004-637X .- 1538-4357. ; 705:1, s. 659-669
  • Tidskriftsartikel (refereegranskat)abstract
    • It was suggested by several authors that hypothetical primordial black holes (PBHs) may contribute to the dark matter (DM) in our Galaxy. There are strong constraints based on the Hawking evaporation that practically exclude PBHs with masses m pbh ~ 1015to1016 g and smaller as significant contributors to the Galactic DM. Similarly, PBHs with masses greater than about 1026 g are practically excluded by the gravitational lensing observation. The mass range between 1016 g
  •  
6.
  • Aulchenko, Yurii S, et al. (författare)
  • Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts
  • 2009
  • Ingår i: Nature Genetics. - : Springer Science and Business Media LLC. - 1061-4036 .- 1546-1718. ; 41:1, s. 47-55
  • Tidskriftsartikel (refereegranskat)abstract
    • Recent genome-wide association (GWA) studies of lipids have been conducted in samples ascertained for other phenotypes, particularly diabetes. Here we report the first GWA analysis of loci affecting total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides sampled randomly from 16 population-based cohorts and genotyped using mainly the Illumina HumanHap300-Duo platform. Our study included a total of 17,797-22,562 persons, aged 18-104 years and from geographic regions spanning from the Nordic countries to Southern Europe. We established 22 loci associated with serum lipid levels at a genome-wide significance level (P < 5 x 10(-8)), including 16 loci that were identified by previous GWA studies. The six newly identified loci in our cohort samples are ABCG5 (TC, P = 1.5 x 10(-11); LDL, P = 2.6 x 10(-10)), TMEM57 (TC, P = 5.4 x 10(-10)), CTCF-PRMT8 region (HDL, P = 8.3 x 10(-16)), DNAH11 (LDL, P = 6.1 x 10(-9)), FADS3-FADS2 (TC, P = 1.5 x 10(-10); LDL, P = 4.4 x 10(-13)) and MADD-FOLH1 region (HDL, P = 6 x 10(-11)). For three loci, effect sizes differed significantly by sex. Genetic risk scores based on lipid loci explain up to 4.8% of variation in lipids and were also associated with increased intima media thickness (P = 0.001) and coronary heart disease incidence (P = 0.04). The genetic risk score improves the screening of high-risk groups of dyslipidemia over classical risk factors.
  •  
7.
  • Bergman, Peter, et al. (författare)
  • Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection
  • 2006
  • Ingår i: Infection and Immunity. - 0019-9567 .- 1098-5522. ; 74:12, s. 6982-6991
  • Tidskriftsartikel (refereegranskat)abstract
    • Antimicrobial peptides are present in most living species and constitute important effector molecules of innate immunity. Recently, we and others have detected antimicrobial peptides in the brain. This is an organ that is rarely infected, which has mainly been ascribed to the protective functions of the blood-brain barrier (BBB) and meninges. Since the bactericidal properties of the BBB and meninges are not known, we hypothesized that antimicrobial peptides could play a role in these barriers. We addressed this hypothesis by infecting mice with the neuropathogenic bacterium Neisseria meningitidis. Brains were analyzed for expression of the antimicrobial peptide CRAMP by immunohistochemistry in combination with confocal microscopy. After infection, we observed induction of CRAMP in endothelial cells of the BBB and in cells of the meninges. To explore the functional role of CRAMP in meningococcal disease, we infected mice deficient of the CRAMP gene. Even though CRAMP did not appear to protect the brain from invasion of meningococci, CRAMP knockout mice were more susceptible to meningococcal infection than wild-type mice and exhibited increased meningococcal growth in blood, liver, and spleen. Moreover, we could demonstrate that carbonate, a compound that accumulates in the circulation during metabolic acidosis, makes meningococci more susceptible to CRAMP.
  •  
8.
  •  
9.
  • Lange, Vinzenz, et al. (författare)
  • Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring
  • 2008
  • Ingår i: Molecular & Cellular Proteomics. - 1535-9484. ; 7:8, s. 1489-1500
  • Tidskriftsartikel (refereegranskat)abstract
    • In many studies, particularly in the field of systems biology, it is essential that identical protein sets are precisely quantified in multiple samples such as those representing differentially perturbed cell states. The high degree of reproducibility required for such experiments has not been achieved by classical mass spectrometry-based proteomics methods. In this study we describe the implementation of a targeted quantitative approach by which predetermined protein sets are first identified and subsequently quantified at high sensitivity reliably in multiple samples. This approach consists of three steps. First, the proteome is extensively mapped out by multidimensional fractionation and tandem mass spectrometry, and the data generated are assembled in the PeptideAtlas database. Second, based on this proteome map, peptides uniquely identifying the proteins of interest, proteotypic peptides, are selected, and multiple reaction monitoring (MRM) transitions are established and validated by MS2 spectrum acquisition. This process of peptide selection, transition selection, and validation is supported by a suite of software tools, TIQAM (Targeted Identification for Quantitative Analysis by MRM), described in this study. Third, the selected target protein set is quantified in multiple samples by MRM. Applying this approach we were able to reliably quantify low abundance virulence factors from cultures of the human pathogen Streptococcus pyogenes exposed to increasing amounts of plasma. The resulting quantitative protein patterns enabled us to clearly define the subset of virulence proteins that is regulated upon plasma exposure.
  •  
10.
  • Nilsson, K Peter R, et al. (författare)
  • Solution structure of chi-conopeptide MrIA, a modulator of the human norepinephrine transporter.
  • 2005
  • Ingår i: Biopolymers. - : Wiley. - 0006-3525 .- 1097-0282. ; 80:6, s. 815-823
  • Tidskriftsartikel (refereegranskat)abstract
    • The chi-conopeptides MrIA and MrIB are 13-residue peptides with two disulfide bonds that inhibit human and rat norepinephrine transporter systems and are of significant interest for the design of novel drugs involved in pain treatment. In the current study we have determined the solution structure of MrIA using NMR spectroscopy. The major element of secondary structure is a beta-hairpin with the two strands connected by an inverse gamma-turn. The residues primarily involved in activity have previously been shown to be located in the turn region (Sharpe, I. A.; Palant, E.; Schroder, C. I.; Kaye, D. M.; Adams, D. J.; Alewood, P. F.; Lewis, R. J. J Biol Chem 2003, 278, 40317-40323), which appears to be more flexible than the beta-strands based on disorder in the ensemble of calculated structures. Analogues of MrIA with N-terminal truncations indicate that the N-terminal residues play a role in defining a stable conformation and the native disulfide connectivity. In particular, noncovalent interactions between Val3 and Hyp12 are likely to be involved in maintaining a stable conformation. The N-terminus also affects activity, as a single N-terminal deletion introduced additional pharmacology at rat vas deferens, while deleting the first two amino acids reduced chi-conopeptide potency.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 13
Typ av publikation
tidskriftsartikel (10)
konferensbidrag (3)
Typ av innehåll
refereegranskat (12)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Ferrari, P. (1)
Aaltonen, Pertti (1)
Amory, John K (1)
Anderson, Richard A (1)
Behre, Hermann M (1)
Bialy, Gabriel (1)
visa fler...
Blithe, Diana (1)
Bone, Wilhelm (1)
Bremner, William J (1)
Colvard, Doug (1)
Cooper, Trevor G (1)
Elliesen, Jörg (1)
Gabelnick, Henry L (1)
Gu, Yi-Qun (1)
Handelsman, David J (1)
Johansson, Elof A B (1)
Kersemaekers, Wendy (1)
Liu, Peter (1)
MacKay, Trent (1)
Matlin, Stephen (1)
Mbizvo, Michael (1)
McLachlan, Robert I (1)
Meriggiola, Maria Cr ... (1)
Mletzko, Stephan (1)
Mommers, Ellen (1)
Muermans, Hilde (1)
Nieschlag, Eberhard (1)
Odlind, Viveca (1)
Page, Stephanie T (1)
Radlmaier, Albert (1)
Sitruk-Ware, Regine (1)
Swerdloff, Ronald (1)
Wang, Christina (1)
Wu, Frederick (1)
Zitzmann, Michael (1)
Tjonneland, A (1)
Olsen, A (1)
Tuomisto, F. (1)
Kaaks, Rudolf (1)
Bueno-de-Mesquita, H ... (1)
Key, Timothy J (1)
Riboli, Elio (1)
Linseisen, J. (1)
Rohrmann, S. (1)
Clavel-Chapelon, F. (1)
Sacerdote, C. (1)
Saieva, C. (1)
Slimani, N. (1)
Riboli, E. (1)
Johansson, Fredrik (1)
visa färre...
Lärosäte
Göteborgs universitet (4)
Uppsala universitet (4)
Umeå universitet (2)
Linköpings universitet (2)
Lunds universitet (2)
Chalmers tekniska högskola (2)
visa fler...
Karolinska Institutet (2)
Örebro universitet (1)
visa färre...
Språk
Engelska (13)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (6)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy